Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Dec 23

PMID 36551731

Authors

Kharimat Lora Alatise

Samantha Gardner

Angela Alexander-Bryant

Affiliations

Soon will be listed here.

Abstract

In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, with ovarian cancer being the most lethal. One of the hallmark characteristics of ovarian cancer is the development of resistance to chemotherapeutics. While the exact mechanisms of chemoresistance are poorly understood, it is known that changes at the cellular and molecular level make chemoresistance challenging to treat. Improved therapeutic options are needed to target these changes at the molecular level. Using a precision medicine approach, such as gene therapy, genes can be specifically exploited to resensitize tumors to therapeutics. This review highlights traditional and novel gene targets that can be used to develop new and improved targeted therapies, from drug efflux proteins to ovarian cancer stem cells. The review also addresses the clinical relevance and landscape of the discussed gene targets.

Citing Articles

Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use?.

Asante D, Tierno D, Grassi G, Scaggiante B Int J Mol Sci. 2025; 26(5).

PMID: 40076521 PMC: 11900478. DOI: 10.3390/ijms26051889.

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models.

Stasiak P, Sopel J, Lipowicz J, Rawluszko-Wieczorek A, Korbecki J, Januchowski R Int J Mol Sci. 2025; 26(3).

PMID: 39940891 PMC: 11817197. DOI: 10.3390/ijms26031124.

Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.

Shirani N, Abdi N, Chehelgerdi M, Yaghoobi H, Chehelgerdi M Front Cell Dev Biol. 2025; 13:1485422.

PMID: 39925739 PMC: 11802832. DOI: 10.3389/fcell.2025.1485422.

Regulator of G protein signaling-1 facilitates ovarian cancer development by modulating NF-kB signal pathway.

Shengnan L, Jiayan X, Meng S, Li L, Shengyun C, Mingjuan X Sci Rep. 2025; 15(1):864.

PMID: 39757280 PMC: 11701083. DOI: 10.1038/s41598-024-85071-y.

References

Chandele A, Prasad V, Jagtap J, Shukla R, Shastry P . Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia. 2004; 6(1):29-40. PMC: 1679816. DOI: 10.1016/s1476-5586(04)80051-4. View

Mattarocci S, Hafner L, Lezaja A, Shyian M, Shore D . Rif1: A Conserved Regulator of DNA Replication and Repair Hijacked by Telomeres in Yeasts. Front Genet. 2016; 7:45. PMC: 4811881. DOI: 10.3389/fgene.2016.00045. View

Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand S . Functionally Null Missense Mutation Associates Strongly with Ovarian Carcinoma. Cancer Res. 2017; 77(16):4517-4529. DOI: 10.1158/0008-5472.CAN-17-0190. View

Rosenberg E, Taher M, Kuemmerle N, FARNSWORTH J, Valerie K . A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res. 2001; 61(2):764-70. View

Garrison J, Ge C, Che L, Pullum D, Peng G, Khan S . Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents. J Cancer Sci Ther. 2015; 7(4):121-126. PMC: 4504245. DOI: 10.4172/1948-5956.1000335. View

Kirschner K, Melton D . Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010; 30(9):3223-32. View

Mei Y, Peng C, Liu Y, Wang J, Zhou H . Silencing RIF1 decreases cell growth, migration and increases cisplatin sensitivity of human cervical cancer cells. Oncotarget. 2018; 8(63):107044-107051. PMC: 5739795. DOI: 10.18632/oncotarget.22315. View

Maliepaard M, van Gastelen M, de Jong L, Pluim D, van Waardenburg R, Floot B . Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999; 59(18):4559-63. View

Penson R, Oliva E, Skates S, Glyptis T, Fuller Jr A, Goodman A . Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004; 93(1):98-106. DOI: 10.1016/j.ygyno.2003.11.053. View

10.

Ricci J, Lovato D, Severns V, Sklar L, Larson R . Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts. Mol Cancer Ther. 2016; 15(12):2853-2862. PMC: 5136347. DOI: 10.1158/1535-7163.MCT-15-0789. View

11.

Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H . Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol. 2004; 6(9):849-60. DOI: 10.1038/ncb1159. View

12.

Zhu X, Cai H, Zhao L, Ning L, Lang J . CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017; 8(38):64607-64621. PMC: 5610030. DOI: 10.18632/oncotarget.19929. View

13.

Sawant A, Floyd A, Dangeti M, Lei W, Sobol R, Patrick S . Differential role of base excision repair proteins in mediating cisplatin cytotoxicity. DNA Repair (Amst). 2017; 51:46-59. PMC: 5328804. DOI: 10.1016/j.dnarep.2017.01.002. View

14.

Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson D . The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002; 277(47):45162-71. DOI: 10.1074/jbc.M206882200. View

15.

Subramanian M, Pilli T, Bhattacharya P, Pacini F, Nikiforov Y, Kanteti P . Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab. 2009; 94(4):1467-71. PMC: 2682475. DOI: 10.1210/jc.2008-2378. View

16.

Li R, Chen B, Zhou Y, Guo R, Shuai M, Zeng J . Expression and clinical significance of Apollon in esophageal squamous cell carcinoma. Mol Med Rep. 2016; 14(3):1933-40. PMC: 4991688. DOI: 10.3892/mmr.2016.5473. View

17.

Golks A, Brenner D, Fritsch C, Krammer P, Lavrik I . c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem. 2005; 280(15):14507-13. DOI: 10.1074/jbc.M414425200. View

18.

Liu J, Fletcher B, Page C, Hu C, Nunez G, Baker V . Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol. 1998; 70(3):398-403. DOI: 10.1006/gyno.1998.5125. View

19.

Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, Brynychova V, Mrhalova M, Kodet R . The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics. 2013; 102(2):96-101. DOI: 10.1016/j.ygeno.2013.03.005. View

20.

Cole S, Bhardwaj G, Gerlach J, MACKIE J, Grant C, Almquist K . Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258(5088):1650-4. DOI: 10.1126/science.1360704. View